Literature DB >> 21663988

Comparison of intensity-modulated radiotherapy, adaptive radiotherapy, proton radiotherapy, and adaptive proton radiotherapy for treatment of locally advanced head and neck cancer.

Charles B Simone1, David Ly, Tu D Dan, John Ondos, Holly Ning, Arnaud Belard, John O'Connell, Robert W Miller, Nicole L Simone.   

Abstract

BACKGROUND AND
PURPOSE: Various radiotherapy planning methods for locally advanced squamous cell carcinoma of the head and neck (SCCHN) have been proposed to decrease normal tissue toxicity. We compare IMRT, adaptive IMRT, proton therapy (IMPT), and adaptive IMPT for SCCHN.
MATERIALS AND METHODS: Initial and re-simulation CT images from 10 consecutive patients with SCCHN were used to quantify dosimetric differences between photon and proton therapy. Contouring was performed on both CTs, and plans (n=40 plans) and dose-volume histograms were generated.
RESULTS: The mean GTV volume decreased 53.4% with re-simulation. All plans provided comparable PTV coverage. Compared with IMRT, adaptive IMRT significantly reduced the maximum dose to the mandible (p=0.020) and mean doses to the contralateral parotid gland (p=0.049) and larynx (p=0.049). Compared with IMRT and adaptive IMRT, IMPT significantly lowered the maximum doses to the spinal cord (p<0.002 for both) and brainstem (p<0.002 for both) and mean doses to the larynx (p<0.002 for both) and ipsilateral (p=0.004 IMRT, p=0.050 adaptive) and contralateral (p<0.002 IMRT, p=0.010 adaptive) parotid glands. Adaptive IMPT significantly reduced doses to all critical structures compared with IMRT and adaptive IMRT and several critical structures compared with non-adaptive IMPT.
CONCLUSIONS: Although adaptive IMRT reduced dose to several normal structures compared with standard IMRT, non-adaptive proton therapy had a more favorable dosimetric profile than IMRT or adaptive IMRT and may obviate the need for adaptive planning. Protons allowed significant sparing of the spinal cord, parotid glands, larynx, and brainstem and should be considered for SCCHN to decrease normal tissue toxicity while still providing optimal tumor coverage. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21663988      PMCID: PMC3174314          DOI: 10.1016/j.radonc.2011.05.028

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  36 in total

1.  Methodologies and tools for proton beam design for lung tumors.

Authors:  M F Moyers; D W Miller; D A Bush; J D Slater
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-04-01       Impact factor: 7.038

2.  Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma.

Authors:  G Calais; M Alfonsi; E Bardet; C Sire; T Germain; P Bergerot; B Rhein; J Tortochaux; P Oudinot; P Bertrand
Journal:  J Natl Cancer Inst       Date:  1999-12-15       Impact factor: 13.506

3.  Boosting the tumor bed from deep-seated tumors in early-stage breast cancer: a planning study between electron, photon, and proton beams.

Authors:  José I Toscas; Dolors Linero; Isabel Rubio; Alberto Hidalgo; Raquel Arnalte; Lluís Escudé; Luca Cozzi; Antonella Fogliata; Raymond Miralbell
Journal:  Radiother Oncol       Date:  2010-06-09       Impact factor: 6.280

4.  Helical tomotherapy and intensity modulated proton therapy in the treatment of early stage prostate cancer: a treatment planning comparison.

Authors:  Marco Schwarz; Alessio Pierelli; Claudio Fiorino; Francesco Fellin; Giovanni Mauro Cattaneo; Cesare Cozzarini; Nadia Di Muzio; Riccardo Calandrino; Lamberto Widesott
Journal:  Radiother Oncol       Date:  2010-12-20       Impact factor: 6.280

5.  Adaptive replanning strategies accounting for shrinkage in head and neck IMRT.

Authors:  Qiuwen Wu; Yuwei Chi; Peter Y Chen; Daniel J Krauss; Di Yan; Alvaro Martinez
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-11-01       Impact factor: 7.038

6.  Assessment by a deformable registration method of the volumetric and positional changes of target volumes and organs at risk in pharyngo-laryngeal tumors treated with concomitant chemo-radiation.

Authors:  Pierre Castadot; Xavier Geets; John Aldo Lee; Nicolas Christian; Vincent Grégoire
Journal:  Radiother Oncol       Date:  2010-04-10       Impact factor: 6.280

7.  Evaluation of the radiobiological impact of anatomic modifications during radiation therapy for head and neck cancer: can we simply summate the dose?

Authors:  Jonathan Orban de Xivry; Pierre Castadot; Guillaume Janssens; John Aldo Lee; Xavier Geets; Vincent Grégoire; Benoît Macq
Journal:  Radiother Oncol       Date:  2010-06-11       Impact factor: 6.280

Review 8.  Implications of quantitative tumor and nodal regression rates for nasopharyngeal carcinomas after 45 Gy of radiotherapy.

Authors:  F M Fang; W L Tsai; S F Go; M W Ho; J M Wu; C J Wang; C Y Su; W C Chen; E Y Huang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-15       Impact factor: 7.038

9.  Double-scattered proton-based stereotactic body radiotherapy for stage I lung cancer: a dosimetric comparison with photon-based stereotactic body radiotherapy.

Authors:  Bradford S Hoppe; Soon Huh; Stella Flampouri; Romaine C Nichols; Kenneth R Oliver; Christopher G Morris; Nancy P Mendenhall; Zuofeng Li
Journal:  Radiother Oncol       Date:  2010-10-09       Impact factor: 6.280

10.  Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer.

Authors:  Joseph K Salama; Robert I Haddad; Merril S Kies; Paul M Busse; Lei Dong; David M Brizel; Avraham Eisbruch; Roy B Tishler; Andy M Trotti; Adam S Garden
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-04-11       Impact factor: 7.038

View more
  38 in total

Review 1.  Radiotherapy for head and neck tumours in 2012 and beyond: conformal, tailored, and adaptive?

Authors:  Vincent Grégoire; Robert Jeraj; John Aldo Lee; Brian O'Sullivan
Journal:  Lancet Oncol       Date:  2012-06-28       Impact factor: 41.316

2.  Multifield optimization intensity modulated proton therapy for head and neck tumors: a translation to practice.

Authors:  Steven J Frank; James D Cox; Michael Gillin; Radhe Mohan; Adam S Garden; David I Rosenthal; G Brandon Gunn; Randal S Weber; Merrill S Kies; Jan S Lewin; Mark F Munsell; Matthew B Palmer; Narayan Sahoo; Xiaodong Zhang; Wei Liu; X Ronald Zhu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-05-24       Impact factor: 7.038

3.  A dosimetric comparison of proton and intensity modulated radiation therapy in pediatric rhabdomyosarcoma patients enrolled on a prospective phase II proton study.

Authors:  Matthew M Ladra; Samantha K Edgington; Anita Mahajan; David Grosshans; Jackie Szymonifka; Fazal Khan; Maryam Moteabbed; Alison M Friedmann; Shannon M MacDonald; Nancy J Tarbell; Torunn I Yock
Journal:  Radiother Oncol       Date:  2014-10-16       Impact factor: 6.280

4.  Comparison of mean radiation dose and dosimetric distribution to tooth-bearing regions of the mandible associated with proton beam radiation therapy and intensity-modulated radiation therapy for ipsilateral head and neck tumor.

Authors:  Adepitan A Owosho; SaeHee K Yom; Zhiqiang Han; Kevin Sine; Nancy Y Lee; Joseph M Huryn; Cherry L Estilo
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2016-07-19

5.  Adaptive Radiotherapy for Head Neck Cancer.

Authors:  Shrikant Balasaheb Mali
Journal:  J Maxillofac Oral Surg       Date:  2016-02-22

6.  Intensity-modulated proton therapy and osteoradionecrosis in oropharyngeal cancer.

Authors:  Wencheng Zhang; Xiaodong Zhang; Pei Yang; Pierre Blanchard; Adam S Garden; Brandon Gunn; C David Fuller; Mark Chambers; Katherine A Hutcheson; Rong Ye; Stephen Y Lai; Mohamed Abdallah Sherif Radwan; X Ron Zhu; Steven J Frank
Journal:  Radiother Oncol       Date:  2017-05-23       Impact factor: 6.280

7.  The prevalence and risk factors associated with osteoradionecrosis of the jaw in oral and oropharyngeal cancer patients treated with intensity-modulated radiation therapy (IMRT): The Memorial Sloan Kettering Cancer Center experience.

Authors:  Adepitan A Owosho; C Jillian Tsai; Ryan S Lee; Haley Freymiller; Arvin Kadempour; Spyridon Varthis; Adi Z Sax; Evan B Rosen; SaeHee K Yom; Joseph Randazzo; Esther Drill; Elyn Riedel; Snehal Patel; Nancy Y Lee; Joseph M Huryn; Cherry L Estilo
Journal:  Oral Oncol       Date:  2016-12-03       Impact factor: 5.337

8.  AAR-RT - A system for auto-contouring organs at risk on CT images for radiation therapy planning: Principles, design, and large-scale evaluation on head-and-neck and thoracic cancer cases.

Authors:  Xingyu Wu; Jayaram K Udupa; Yubing Tong; Dewey Odhner; Gargi V Pednekar; Charles B Simone; David McLaughlin; Chavanon Apinorasethkul; Ontida Apinorasethkul; John Lukens; Dimitris Mihailidis; Geraldine Shammo; Paul James; Akhil Tiwari; Lisa Wojtowicz; Joseph Camaratta; Drew A Torigian
Journal:  Med Image Anal       Date:  2019-01-29       Impact factor: 8.545

Review 9.  Charged particle therapy--optimization, challenges and future directions.

Authors:  Jay S Loeffler; Marco Durante
Journal:  Nat Rev Clin Oncol       Date:  2013-05-21       Impact factor: 66.675

10.  Beam path toxicity in candidate organs-at-risk: assessment of radiation emetogenesis for patients receiving head and neck intensity modulated radiotherapy.

Authors:  Esengul Kocak-Uzel; G Brandon Gunn; Rivka R Colen; Micheal E Kantor; Abdallah S R Mohamed; Sara Schoultz-Henley; Paniyotis Mavroidis; Steven J Frank; Adam S Garden; Beth M Beadle; William H Morrison; Jack Phan; David I Rosenthal; Clifton D Fuller
Journal:  Radiother Oncol       Date:  2014-04-17       Impact factor: 6.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.